Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 21050119)

1.

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Gisslén M.

J Infect Dis. 2010 Dec 15;202(12):1819-25. doi: 10.1086/657342. Epub 2010 Nov 4.

2.

Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.

PMID:
23018371
3.

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73.

4.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

5.

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, Svennerholm B, Gisslén M.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):590-6. doi: 10.1097/QAI.0b013e3181f5b3d1.

PMID:
20847699
6.

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

Scand J Infect Dis. 2004;36(11-12):823-8.

PMID:
15764168
7.

Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.

Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):544-52. doi: 10.1097/QAI.0b013e318162754f.

8.

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, Cinque P, Spudich S.

AIDS. 2012 Sep 10;26(14):1765-74. doi: 10.1097/QAD.0b013e328355e6b2.

9.

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

Kravcik S, Gallicano K, Roth V, Cassol S, Hawley-Foss N, Badley A, Cameron DW.

J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):371-5.

PMID:
10458617
10.

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A.

J Infect. 2012 Sep;65(3):239-45. doi: 10.1016/j.jinf.2012.04.007. Epub 2012 Apr 17.

PMID:
22522289
11.

Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.

Gisslén M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):291-5.

PMID:
9525428
12.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
14.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group.

Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.

15.

Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.

Spudich S, Lollo N, Liegler T, Deeks SG, Price RW.

J Infect Dis. 2006 Dec 15;194(12):1686-96. Epub 2006 Nov 3.

16.

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.

Arvidson N, Gisslén M, Albert J, Brandin E, Svennerholm B, Fuchs D, Hagberg L.

AIDS Res Hum Retroviruses. 2004 Jul;20(7):711-5.

PMID:
15307916
17.

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, Ofotokun I.

J Clin Pharmacol. 2014 Sep;54(9):1063-71. doi: 10.1002/jcph.298. Epub 2014 Apr 8.

PMID:
24691856
19.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, Pumarola T, Gallart T, Miró JM, Gatell JM.

AIDS. 1999 Jul 30;13(11):F79-86.

PMID:
10449278
20.

Viral escape in cerebrospinal fluid--an achilles heel of HIV therapy?

Clifford DB.

J Infect Dis. 2010 Dec 15;202(12):1768-9. doi: 10.1086/657343. Epub 2010 Nov 4. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk